Evaluation of the berberis vulgaris effects against leishmaniasis

Evaluation of the protective effects of berberis vulgaris roots nanoliposome against cutaneous leishmaniasis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240510061730N1

Enrollment

Registered

2024-06-07

Start date

2024-06-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention group: Patients who apply a 2 mm thick layer of nanoliposomal cream containing berberis vulgaris extract twice a day for 8 weeks and bandage it.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: positive leishmaniosis disease (except face) not pregnant ages: 20-70 y not other diseases normal kidney and liver tests

Exclusion criteria

Exclusion criteria: Facial lesions pregnancy and lactation Immunosuppressive medications

Design outcomes

Primary

Measure	Time frame
Lesion size. Timepoint: Measurement of lesion size before starting treatment, every week during treatment (0 to 8). Method of measurement: Complete recovery: 100% healing of the wound and its secretions, Significant healing: healing between 76 and 99 percent, Partial healing: healing between 51 and 75%, Partial recovery: recovery between 26 and 50%, Non-healing: reducing the size of the wound to less than 26%, Treatment failure: no change in wound size or discharge.	—

Measure

Time frame

Lesion size. Timepoint: Measurement of lesion size before starting treatment, every week during treatment (0 to 8). Method of measurement: Complete recovery: 100% healing of the wound and its secretions, Significant healing: healing between 76 and 99 percent, Partial healing: healing between 51 and 75%, Partial recovery: recovery between 26 and 50%, Non-healing: reducing the size of the wound to less than 26%, Treatment failure: no change in wound size or discharge.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Rakhshandeh

Mashhad University of Medical Sciences

rakhshandehh@mums.ac.ir+98 51 3800 2258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026